ANNOUNCEMENT

Launch Viroclinics Xplore Business Unit

6 June, 2019

Due to the growing demand of our global business and the drive to deliver innovative diagnostic services, we are proud to announce the launch of our new business unit, Viroclinics Xplore.

Viroclinics Xplore focuses on early stage, preclinical contract research services. Throughout the years, Viroclinics invested heavily in its preclinical facilities to cope with the increasing demand in the market. This resulted in the establishment of a 1600 m2 preclinical facility. After establishing a solid portfolio of viral targets such as influenza, Viroclinics became a recognized partner for polio eradication.

Preclinical contract research services are at the core of our company. With Viroclinics Xplore we are able to better serve our customer´s specialized needs, without losing focus on our integrated service platform, designed around all phases of anti-viral drug and vaccine development.

The launch of Viroclinics Xplore is in line with Viroclinics´ growth ambitions and allows for the opportunity to expand our fields of expertise and service portfolio. The establishment of the new business unit has no impact/ effect on current and/ or future studies and projects. The business and its operational activities will continue as usual. You can be assured of Viroclinics’ usual high quality service delivery.

Should you have any further questions, please feel free to contact your usual Viroclinics representative or alternatively contact us on: marketing@viroclinics.com or via: T. +31 88 668 4771.